Vaxcyte, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 12, 2020 and accepted by EDGAR at Nov 12, 2020, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2020-07-01 to 2020-09-30 | $16.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $58.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$21.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$70.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $7.0k | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$21.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$68.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.41 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$3.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$35.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $433.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $397.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $400.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $403.8m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $39.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $39.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $364.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-053540. Last ingested by Listed: Nov 4, 2026, 18:37 ET. Listed shows no prices and gives no investment advice.